You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

19 search results for: itch

<b>Itch</b> in AD, PN, and CSU: Contributions of Type 2 Inflammation

expert video

Itch in AD, PN, and CSU: Contributions of Type 2 Inflammation

13 min

Dermatology

In this video from the ADVENT symposium from Fall Clinical 2023, join Dr. Raj Chovatiya as he explores the contribution of type 2 inflammation to itch in AD, PN, and CSU.

Disease-Specific Aspects of <b>Itch</b> in AD, PN, and CSU

expert video

Disease-Specific Aspects of Itch in AD, PN, and CSU

16 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

Unique Characteristics of <b>Itch</b> in AD, PN, and CSU – A Panel Discussion

expert video

Unique Characteristics of Itch in AD, PN, and CSU – A Panel Discussion

5 min

Dermatology

Dr. Kim and Dr. Elmariah discuss how unique characteristics of itch in AD, PN, and CSU impact patients.

expert video

A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria

45 min

Dermatology

Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type 2 cytokines at the neuroimmune axis In PN and CSU

expert video

Characteristics of Chronic Itch in PN and CSU

2 min

Dermatology

Professor Metz demonstrates the unique characteristics of chronic itch in PN and CSU, and the corresponding disease-specific burdens associated with chronic itch

expert video

Itch and Inflammation in Two Distinct Diseases: PN and CSU

20 min

Dermatology

Professor Metz discusses the unique clinical presentations of PN and CSU and explores the shared and distinct cellular underpinnings of itch and inflammation in both diseases

interactivity

Type 2 Inflammation and Neuronal Sensitization in AD and PN

5 min

Dermatology

Mechanisms of itch in normal skin and the effect of type 2 inflammation on neurons leading to chronic itch in atopic dermatitis and prurigo nodularis.

expert video

Contributions of Type 2 Cytokines to Chronic Pruritus in AD, PN, and CSU

2 min

Dermatology

Dr. Elmariah introduces the multiple roles of type 2 cytokines in chronic itch.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

AD, PN, and CSU: Distinct, Pruritic Diseases

1 min

Dermatology

Dr. Elmariah explains how AD, PN, and CSU are distinct diseases with the common, burdensome symptom of itch.

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

expert video

CSU is Associated With a High Burden and Impact on Quality of Life

2 min

Dermatology

Dr. Casale discusses delays in diagnosing CSU, the impact of severe itch on daily life and mental health, and the challenges in achieving remission.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region